Research Guide
A clear TB-500 dosage guide covering loading and maintenance protocols, injection amounts, reconstitution math, BPC-157 stacking and cited safety evidence.
If you are researching TB-500 dosage, it helps to separate this thymosin beta-4 fragment from BPC-157 instead of treating the two as interchangeable. This guide covers what published studies tested, common loading and maintenance references, and what remains unknown.
Educational and research information only. Nothing here is medical advice, prescribing guidance or a recommendation to use any compound. Consult a licensed healthcare professional before any health decision.
Thymosin beta-4 is one of the most abundant actin-binding proteins in mammalian cells, and animal work links it to cell migration, new blood-vessel formation and reduced fibrosis in cardiac, corneal and dermal injury models. TB-500 is a synthetic fragment intended to reproduce the active portion of that protein.
Human trials of full-length thymosin beta-4 have been run in limited wound and eye indications, but the synthetic fragment sold as TB-500 has no equivalent trial base. Every dose band below is extrapolated.
Reference protocols describe subcutaneous administration from a reconstituted vial drawn into a U-100 insulin syringe, with weekly totals rather than daily doses:
Unlike BPC-157, injection site is rarely described as important, since the mechanism is treated as systemic.
Divide vial strength by the volume of bacteriostatic water added to get concentration, then convert to units on a U-100 syringe:
Larger doses often need a second injection rather than one large volume. Add the water slowly down the vial wall, swirl rather than shake, and refrigerate after mixing.
The common structure is a 4 to 6 week loading block followed by maintenance or a break to reassess. TB-500 is paired with BPC-157 more often than it is used alone, and appears in Wolverine, KLOW and dual BPC/TB vials. Combination protocols carry no dedicated human data — understand each component separately first.
The angiogenic and pro-migratory activity behind the repair claims is the same activity that raises unresolved questions about tumour biology, which is a clear reason for caution in anyone with a current or prior cancer diagnosis. Supplier quality varies, so a certificate of analysis matters.
TB-500 is not FDA approved and has been prohibited at all times by WADA as a tissue growth factor.
Published research reference
Trial / research dose bands
Reported side effects
Cited studies
Educational research reference only — not medical advice.
What is TB-500?
TB-500 is a synthetic peptide based on an active region of thymosin beta-4, a naturally occurring protein involved in actin regulation, cell migration and wound repair. Published work is preclinical — animal and cell models of soft-tissue, cardiac and corneal repair — with no large human clinical trials for the synthetic fragment.
What is the dosage for TB-500?
Reference protocols usually describe a loading phase of roughly 2 to 5 mg per week, split into two injections, for the first 4 to 6 weeks, followed by a maintenance band of about 2 mg every one to two weeks. These are research-planning bands extrapolated from animal work, not validated human doses.
How is TB-500 reconstituted?
A lyophilised vial is reconstituted with bacteriostatic water added slowly down the vial wall, then swirled rather than shaken. A 5 mg vial with 2 mL of bacteriostatic water gives 2.5 mg/mL, so a 2.5 mg dose is 1 mL, or 100 units on a U-100 insulin syringe.
How long does TB-500 stay active?
TB-500 is described as having a longer functional duration than most repair peptides, which is why weekly or twice-weekly dosing appears in reference protocols instead of daily injections. Precise human pharmacokinetics are not established.
Is TB-500 usually combined with BPC-157?
Yes — the two appear together constantly in soft-tissue research planning and in blends such as Wolverine, KLOW and BPC/TB dual vials. The rationale is complementary mechanisms, but the combination itself has no dedicated human trial data.
Is TB-500 approved, and is it banned in sport?
It is not an FDA-approved drug. WADA prohibits TB-500 at all times as a growth factor affecting tissue regeneration, so tested athletes should not use it.
What are the main safety concerns?
As with other angiogenic repair peptides, the theoretical concern is that the same pathways supporting tissue regeneration could support tumour growth. Long-term human safety data does not exist, and product purity varies by supplier.
Track it properly
Members log doses, cycles and outcomes in one place, compare compounds side by side and read the full Peptide Academy breakdown for every compound in this guide.